Hemoglobin C disease is a blood disorder passed down through families. It leads to a type of anemia, which occurs when red blood cells break down earlier than normal.
Clinical hemoglobin C
Hemoglobin C is an abnormal type of hemoglobin, the protein in red blood cells that carries oxygen. It is a type of hemoglobinopathy. The disease is caused by a problem with a gene called beta globin.
The disease most often occurs in African Americans. You are more likely to have hemoglobin C disease if someone in your family has had it.
Most people do not have symptoms. In some cases, jaundice may occur. Some people may develop gallstones that need to be treated.
In most cases, no treatment is needed. Folic acid supplements may help your body produce normal red blood cells and improve the symptoms of the anemia.
Nathalie Lemonne practices in Pointe-à-pitre, Guadeloupe. Lemonne is rated as an Elite expert by MediFind in the treatment of Hemoglobin C Disease. She is also highly rated in 10 other conditions, according to our data. Her top areas of expertise are Hemoglobin C Disease, Sickle Cell Disease, Congenital Hemolytic Anemia, and Hemoglobinopathy.
Ogobara Doumbo practices in Bamako, Mali. Doumbo is rated as an Elite expert by MediFind in the treatment of Hemoglobin C Disease. They are also highly rated in 13 other conditions, according to our data. Their top areas of expertise are Malaria, Hemoglobin C Disease, Primary Amebic Meningoencephalitis, and Sepsis.
Xavier Waltz practices in Grenoble, France. Waltz is rated as a Distinguished expert by MediFind in the treatment of Hemoglobin C Disease. He is also highly rated in 7 other conditions, according to our data. His top areas of expertise are Hemoglobin C Disease, Sickle Cell Disease, Congenital Hemolytic Anemia, and Hemoglobinopathy.
People with hemoglobin C disease can expect to lead a normal life.
Complications may include:
Contact your health care provider if you have symptoms of hemoglobin C disease.
You may want to seek genetic counseling if you are at high risk for the condition and are considering having a baby.
Summary: The primary objective of this study is to better understand factors contributing to variations in hydroxyurea (HU) adherence behavior in adolescents and young adults (AYA) with sickle cell disease (SCD). To meet this objective, the researchers will conduct a prospective cohort study to determine the longitudinal relationship between HU adherence and health-related quality of life (HRQOL) overtime ...
Summary: The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app). To meet this objective, the researchers will conduct a pilot randomized controlled trial to test the feasibility and acceptability of MED-Go app in adolescents and young adults (AYA) with sickle cell disease (SCD). The long-term goal of this research is to promote medication adherence behavior and ...
Published Date: January 25, 2022
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Howard J. Sickle cell disease and other hemoglobinopathies. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 154.
Smith-Whitley K, Kwiatkowski JL. Hemoglobinopathies. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 489.
So JCC, Ma ESK. Hemoglobin and hemoglobinopathies. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. St Louis, MO: Elsevier; 2023:chap 77.
Wilson CS, Vergara-Lluri ME, Brynes RK. Evaluation of anemia, leukopenia, and thrombocytopenia. In: Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Martinez L, eds. Hematopathology. 2nd ed. Philadelphia, PA: Elsevier; 2017:chap 11.